Palvella Therapeutics (PVLA) Competitors

$108.80 +3.75 (+3.57%)

Closing price 03:59 PM Eastern

Extended Trading

$109.32 +0.52 (+0.48%)

As of 04:04 PM Eastern

PVLA vs. MIRM, BLTE, TERN, CGON, and COGT

Should you buy Palvella Therapeutics stock or one of its competitors? MarketBeat compares Palvella Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Palvella Therapeutics include Mirum Pharmaceuticals (MIRM), Belite Bio (BLTE), Terns Pharmaceuticals (TERN), CG Oncology (CGON), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Palvella Therapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Palvella Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market.

Mirum Pharmaceuticals presently has a consensus target price of $137.08, indicating a potential upside of 43.38%. Palvella Therapeutics has a consensus target price of $199.53, indicating a potential upside of 83.39%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Palvella Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Mirum Pharmaceuticals has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.18	-$23.36M	-$13.61	N/A
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.17	N/A

40.1% of Palvella Therapeutics shares are held by institutional investors. 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 6 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.32 beat Palvella Therapeutics' score of -0.43 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals beats Palvella Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Palvella Therapeutics compare to Belite Bio?

Palvella Therapeutics (NASDAQ:PVLA) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Belite Bio is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.17	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Palvella Therapeutics and Palvella Therapeutics both had 6 articles in the media. Belite Bio's average media sentiment score of 0.00 beat Palvella Therapeutics' score of -0.43 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics presently has a consensus price target of $199.53, suggesting a potential upside of 83.39%. Belite Bio has a consensus price target of $202.33, suggesting a potential upside of 44.97%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Palvella Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Palvella Therapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.19, indicating that its stock price is 219% less volatile than the broader market.

Belite Bio's return on equity of -19.49% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Belite Bio	N/A	-19.49%	-19.05%

Summary

Palvella Therapeutics beats Belite Bio on 9 of the 13 factors compared between the two stocks.

How does Palvella Therapeutics compare to Terns Pharmaceuticals?

Palvella Therapeutics (NASDAQ:PVLA) and Terns Pharmaceuticals (NASDAQ:TERN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Palvella Therapeutics had 5 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 6 mentions for Palvella Therapeutics and 1 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.35 beat Palvella Therapeutics' score of -0.43 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Terns Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Terns Pharmaceuticals' return on equity of -20.02% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Terns Pharmaceuticals	N/A	-20.02%	-19.37%

Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.17	N/A
Terns Pharmaceuticals	N/A	N/A	-$96.21M	-$1.03	N/A

Palvella Therapeutics has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market. Comparatively, Terns Pharmaceuticals has a beta of -0.37, indicating that its share price is 137% less volatile than the broader market.

Palvella Therapeutics currently has a consensus target price of $199.53, suggesting a potential upside of 83.39%. Terns Pharmaceuticals has a consensus target price of $55.14, suggesting a potential upside of 4.13%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Palvella Therapeutics is more favorable than Terns Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Terns Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Palvella Therapeutics beats Terns Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Palvella Therapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Palvella Therapeutics has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,383.47	-$160.99M	-$2.33	N/A
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.17	N/A

CG Oncology currently has a consensus price target of $81.73, suggesting a potential upside of 28.97%. Palvella Therapeutics has a consensus price target of $199.53, suggesting a potential upside of 83.39%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Palvella Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

CG Oncology has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, CG Oncology had 13 more articles in the media than Palvella Therapeutics. MarketBeat recorded 19 mentions for CG Oncology and 6 mentions for Palvella Therapeutics. CG Oncology's average media sentiment score of -0.01 beat Palvella Therapeutics' score of -0.43 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Palvella Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CG Oncology's return on equity of -23.33% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Summary

Palvella Therapeutics beats CG Oncology on 8 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Palvella Therapeutics' return on equity of -56.87% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Palvella Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.17	N/A

40.1% of Palvella Therapeutics shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cogent Biosciences has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market.

Cogent Biosciences currently has a consensus price target of $43.73, indicating a potential upside of 40.08%. Palvella Therapeutics has a consensus price target of $199.53, indicating a potential upside of 83.39%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Palvella Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

In the previous week, Palvella Therapeutics had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Palvella Therapeutics and 0 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.00 beat Palvella Therapeutics' score of -0.43 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cogent Biosciences	Positive
Palvella Therapeutics	Neutral

Summary

Palvella Therapeutics beats Cogent Biosciences on 9 of the 14 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PVLA vs. The Competition

Export

Metric	Palvella Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.56B	$3.26B	$6.26B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-26.09	18.70	20.61	25.11
Price / Sales	N/A	279.28	577.39	91.11
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	46.10	6.57	9.68	6.62
Net Income	-$41.72M	$24.30M	$3.55B	$335.60M
7 Day Performance	-13.51%	-3.60%	-2.06%	-1.97%
1 Month Performance	-16.31%	-7.89%	-3.88%	-1.83%
1 Year Performance	382.27%	51.82%	29.45%	27.43%

Palvella Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PVLA Palvella Therapeutics	3.1239 of 5 stars	$108.80 +3.6%	$199.53 +83.4%	+376.4%	$1.56B	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	2.8109 of 5 stars	$102.46 -6.9%	$134.75 +31.5%	+112.2%	$6.24B	$521.31M	N/A	140	Analyst Forecast
BLTE Belite Bio	2.1365 of 5 stars	$153.03 -2.0%	$202.33 +32.2%	+121.9%	$6.13B	N/A	N/A	10	Upcoming Earnings
TERN Terns Pharmaceuticals	2.1758 of 5 stars	$52.95 flat	$55.14 +4.1%	+1,738.5%	$6.12B	N/A	N/A	40
CGON CG Oncology	2.7042 of 5 stars	$68.92 +1.3%	$79.55 +15.4%	+147.5%	$6.07B	$4.04M	N/A	61	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PVLA) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palvella Therapeutics (PVLA) Competitors

PVLA vs. MIRM, BLTE, TERN, CGON, and COGT

How does Palvella Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Palvella Therapeutics compare to Belite Bio?

Summary

How does Palvella Therapeutics compare to Terns Pharmaceuticals?

Summary

How does Palvella Therapeutics compare to CG Oncology?

Summary

How does Palvella Therapeutics compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palvella Therapeutics (PVLA) Competitors

PVLA vs. MIRM, BLTE, TERN, CGON, and COGT

How does Palvella Therapeutics compare to Mirum Pharmaceuticals?

Is MIRM or PVLA more profitable?

Which has more volatility and risk, MIRM or PVLA?

Do analysts rate MIRM or PVLA?

Which has preferable earnings & valuation, MIRM or PVLA?

Do insiders and institutionals believe in MIRM or PVLA?

Does the media prefer MIRM or PVLA?

Summary

How does Palvella Therapeutics compare to Belite Bio?

Which has better earnings and valuation, PVLA or BLTE?

Do institutionals & insiders have more ownership in PVLA or BLTE?

Does the media refer more to PVLA or BLTE?

Do analysts rate PVLA or BLTE?

Which has more risk & volatility, PVLA or BLTE?

Is PVLA or BLTE more profitable?

Summary

How does Palvella Therapeutics compare to Terns Pharmaceuticals?

Does the media refer more to PVLA or TERN?

Is PVLA or TERN more profitable?

Which has preferable valuation and earnings, PVLA or TERN?

Which has more volatility & risk, PVLA or TERN?

Do analysts rate PVLA or TERN?

Do insiders & institutionals have more ownership in PVLA or TERN?

Summary

How does Palvella Therapeutics compare to CG Oncology?

Which has better valuation & earnings, CGON or PVLA?

Do analysts rate CGON or PVLA?

Which has more risk and volatility, CGON or PVLA?

Do insiders and institutionals hold more shares of CGON or PVLA?

Does the media favor CGON or PVLA?

Is CGON or PVLA more profitable?

Summary

How does Palvella Therapeutics compare to Cogent Biosciences?

Is COGT or PVLA more profitable?

Which has higher earnings and valuation, COGT or PVLA?

Do insiders & institutionals believe in COGT or PVLA?

Which has more volatility and risk, COGT or PVLA?

Do analysts prefer COGT or PVLA?

Does the media prefer COGT or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools